ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2018

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

M J Maurer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.